Word

UNIQURE

Status

Registered

Status Code

705

Status Date

Thursday, April 1, 2021

Serial Number

85907857

Registration Number

4710280

Registration Date

Tuesday, March 31, 2015

Mark Type

4000

Filing Date

Thursday, April 18, 2013

Published for Opposition

Tuesday, September 2, 2014

Trademark Owner History

uniQure IP B.V. - Original Registrant

Classifications

5 Viral medicines, gene therapy medicines, nucleic acid delivery medicines, viral vectors, [non-viral vectors,] gene therapy vectors, nucleic acid delivery vectors, [and cells transformed by viral vectors, non-viral vectors, gene therapy vectors and nucleic acid delivery vectors] for medical purposes all for medical treatment of metabolic disorders, [ocular disorders,] diseases of the nervous system, blood disorders, liver disorders, [muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases,] inherited disorders, genetic disorders, single gene disorders [and cancers;] pharmaceutical preparations and substances for the treatment of metabolic disorders, [ocular disorders,] diseases of the nervous system, blood disorders, liver disorders, [muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases,] inherited disorders, genetic disorders, single gene disorders [and cancers;] biological preparations for use in medical and clinical gene therapy, nucleic acid-based therapy [and cell therapy,] all for the treatment of metabolic disorders, [ocular disorders,] diseases of the nervous system, blood disorders, liver disorders, [muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases,]inherited disorders, genetic disorders, single gene disorders [and cancers;] [clinical medical reagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnosis and gene testing in the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; pharmaceutical preparations, vaccines, prophylaxis medicines and other] pharmaceutical preparations [all] for use in nucleic acid-based therapy, gene therapy [and cell therapy] in the treatment of metabolic disorders, [ocular disorders,] diseases of the nervous system, blood disorders, liver disorders, [muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases,] inherited disorders, genetic disorders, single gene disorders [and cancers]

1 [Viral assays, viral reagents, viral preparations, gene therapy assays, gene therapy reagents, gene therapy preparations, nucleic acid delivery assays, nucleic acid delivery reagents, nucleic acid delivery preparations, viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors and nucleic acid delivery vectors, all for non-medical research purposes]

44 Gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation for the treatment of metabolic disorders, [ocular disorders,] diseases of the nervous system, blood disorders, liver disorders, [muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders,] inherited disorders, genetic disorders and single gene disorders

42 Research, product development and consultancy in the field of biotechnology, biologics, pharmaceutics, medical science, chemistry and biochemistry

Color is not claimed as a feature of the mark.

Trademark Events

Mar 31, 2024

Courtesy Reminder - Sec. 8 (10-Yr)/Sec. 9 E-Mailed

Apr 1, 2021

Notice Of Acceptance Of Sec. 8 & 15 - E-Mailed

Apr 1, 2021

Registered - Partial Sec. 8 (6-Yr) Accepted & Sec. 15 Ack.

Nov 10, 2020

Case Assigned To Post Registration Paralegal

Sep 17, 2020

Teas Section 8 & 15 Received

Mar 31, 2020

Courtesy Reminder - Sec. 8 (6-Yr) E-Mailed

Mar 31, 2015

Registered-Principal Register

Nov 18, 2014

1(B) Basis Deleted; Proceed To Registration

Oct 29, 2014

Notice Of Allowance Cancelled

Nov 18, 2014

Case Assigned To Intent To Use Paralegal

Oct 29, 2014

Teas Delete 1(B) Basis Received

Oct 28, 2014

Noa E-Mailed - Sou Required From Applicant

Sep 2, 2014

Official Gazette Publication Confirmation E-Mailed

Sep 2, 2014

Published For Opposition

Aug 13, 2014

Notification Of Notice Of Publication E-Mailed

Jul 28, 2014

Law Office Publication Review Completed

Jul 28, 2014

Approved For Pub - Principal Register

Jul 24, 2014

Teas/Email Correspondence Entered

Jul 24, 2014

Correspondence Received In Law Office

Jul 24, 2014

Teas Request For Reconsideration Received

Feb 22, 2014

Notification Of Final Refusal Emailed

Feb 22, 2014

Final Refusal E-Mailed

Feb 22, 2014

Final Refusal Written

Jan 31, 2014

Teas/Email Correspondence Entered

Jan 31, 2014

Correspondence Received In Law Office

Jan 26, 2014

Assigned To Lie

Jan 16, 2014

Teas Response To Office Action Received

Jan 16, 2014

Teas Response To Office Action Received

Aug 5, 2013

Notification Of Non-Final Action E-Mailed

Aug 5, 2013

Non-Final Action E-Mailed

Aug 5, 2013

Non-Final Action Written

Aug 5, 2013

Assigned To Examiner

Apr 25, 2013

New Application Office Supplied Data Entered

Apr 22, 2013

New Application Entered